NexCCS is the most advanced and validated embryo screening platform available for in vitro fertilization (IVF) today.
Validated over several years and multiple rigorous clinical trials, NexCCS can accurately determine if an embryo possesses the right number of chromosomes (euploidy) or too few or too many (aneuploidy). This is important because aneuploidy is the leading cause of IVF failure. Published data also suggests that 50-70% of miscarriages are due to aneuploidy. Selection with NexCCS can substantially reduce these risks.
NexCCS is owned and operated by the Foundation for Embryonic Competence (FEC). All proceeds from NexCCS testing go directly to the FEC and are used to support research and education. Learn more about the Foundation at feclabs.org.
FEATURES OF THE NEXCCS PROCESS:
ONE HEALTHY EMBRYO, ONE HEALTHY BABY
In the U.S., approximately half of all babies conceived following IVF were born as part of a twin or triplet pregnancy. These pregnancies typically result from a multiple embryo transfer and are associated with a significantly increased risk of problems for the mother and baby.
Utilizing NexCCS to choose the single best embryo for transfer makes the promise of Single Embryo Transfer (SET) a reality and provides a safer and more effective treatment option for many patients.
Have questions regarding Comprehensive Chromosome Screening (CCS)? For more information, please contact us today.